{'fraction_non_alphanumeric': 0.03248031496062992, 'fraction_numerical': 0.014763779527559055, 'mean_word_length': 5.126506024096385, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Studies on cisplatinum albumin microspheres for lung targeting].

An optimum procedure was established by orthogonal test for preparing cisplatinum albumin microspheres (CDDP-BSA-MS) with emulsion-chemical cross-linking. The quality, stability, distribution in vivo, kinetic characteristics and safety of the albumin microspheres were studied. The results showed that the surface was regular, the mean size was 13.13 +/- 3.55 microns, embedding ratio was 21.62% and the release characteristics in vitro were in accord with "biphase kinetics equation". The stability of the albumin microspheres was good after three months storage. The microspheres accumulated almost entirely in the lung 15 minutes after intravenous injection to mice. The total amount in the lung was about 97% of the injected dose at the peak concentration. Two-compartmental model can be used to describe the regulation of the pharmacokinetics of albumin microspheres in lung. Observation of the lung slice of mice showed no pathological damage.